Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOB560 + MIK665 in relapsed/refractory NHL, AML, and MM
NCT04702425Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label trial of VOB560 and S64315 in non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML) and multiple myeloma (MM) (6 arms), sponsored by Novartis. Primary endpoints: Adverse Events at 18 months, Dose Limiting Toxicities at Cycle 1 and 3 more. Started Jun 2021; status: terminated.
02
Drugs
VOB560S64315
03
Conditions
non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04702425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702425.